華檢醫療(01931.HK)獲Boxin獨家委聘為戰略伙伴 在中國成立數間醫療測試中心
格隆匯 3 月 12日丨華檢醫療(01931.HK)公吿,於2021年3月8日,公司與獨立第三方Boxin訂立合作協議,據此,公司獲Boxin獨家委聘為戰略伙伴,在中國成立數間醫療測試中心,Boxin應付的總財政預算約人民幣2億元,可由訂約方另行協定作出調整。公司亦負責採購及安裝醫療測試中心的設備及設施,詳情見合作協議。合作協議自該協議日期起計為期五年。Boxin將於合作協議年期內分期向公司支付代價。
Boxin為創新生物科技公司,從事HIV抗藥性測試及治療,總部設於中國。
自2013年起,公司已在中國為六間三級醫院提供解決方案服務。透過擔任有關醫院的臨牀檢驗科的總供應商,集團參與實驗室場地的設計、提供IVD產品集中採購服務、開展實時存貨監控及向臨牀實驗室提供其他售後服務。透過多年營運,集團已積累豐富的運營經驗及多樣化產品組合,因此集團有能力將其推廣到其他醫院及醫療機構。
因此,Boxin成為公司解決方案服務的首名非醫院客户,並根據合作協議委聘公司為在中國成立醫療測試中心的獨家合作伙伴。董事會認為,訂立合作協議顯示公司的解決方案服務已經在IVD行業備受認同,且預期可獲得額外收入來源,為公司股東帶來裨益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.